Literature DB >> 19499273

Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review.

T Gleeson1, M D Iversen, J Avorn, A M Brookhart, J N Katz, E Losina, F May, A R Patrick, W H Shrank, D H Solomon.   

Abstract

SUMMARY: Adherence and persistence with osteoporosis medications are poor. We conducted a systematic literature review of interventions to improve adherence and persistence with osteoporosis medications. Seven studies met eligibility requirements and were included in the review. Few interventions were efficacious, and no clear trends regarding successful intervention techniques were identified. However, periodic follow-up interaction between patients and health professionals appeared to be beneficial.
INTRODUCTION: Adherence and persistence with pharmacologic therapy for osteoporosis are suboptimal. Our goal was to examine the design and efficacy of published interventions to improve adherence and persistence.
METHODS: We searched medical literature databases for English-language papers published between January 1990 and July 2008. We selected papers that described interventions and provided results for control and intervention subjects. We assessed the design and methods of each study, including randomization, blinding, and reporting of drop-outs. We summarized the results and calculated effect sizes for each trial.
RESULTS: Seven studies met eligibility requirements and were included in the review. Five of the seven studies provided adherence data. Of those five studies, three showed a statistically significant (p < or = 0.05) improvement in adherence by the intervention group, with effect sizes from 0.17 to 0.58. Five of the seven studies provided persistence data. Of those five, one reported statistically significant improvement in persistence by the intervention group, with an effect size of 0.36.
CONCLUSIONS: Few interventions were efficacious, and no clear trends regarding successful intervention techniques were identified in this small sample of studies. However, periodic follow-up interaction between patients and health professionals appeared to be beneficial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499273      PMCID: PMC3257053          DOI: 10.1007/s00198-009-0976-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  30 in total

1.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Authors:  A R Jadad; R A Moore; D Carroll; C Jenkinson; D J Reynolds; D J Gavaghan; H J McQuay
Journal:  Control Clin Trials       Date:  1996-02

2.  Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists.

Authors:  D Moher; A R Jadad; G Nichol; M Penman; P Tugwell; S Walsh
Journal:  Control Clin Trials       Date:  1995-02

Review 3.  Predictors of medication adherence in the elderly.

Authors:  R Balkrishnan
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

4.  Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

Authors:  J Reginster; H W Minne; O H Sorensen; M Hooper; C Roux; M L Brandi; B Lund; D Ethgen; S Pack; I Roumagnac; R Eastell
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

5.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

6.  Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.

Authors:  Ann Cranney; Gordon Guyatt; Lauren Griffith; George Wells; Peter Tugwell; Clifford Rosen
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

7.  A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture.

Authors:  Maria-Teresa Cuddihy; Peter C Amadio; Sherine E Gabriel; V Shane Pankratz; Robert L Kurland; L Joseph Melton
Journal:  Osteoporos Int       Date:  2004-03-09       Impact factor: 4.507

8.  The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial.

Authors:  Jackie A Clowes; Nicola F A Peel; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

9.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Authors:  S R Cummings; D M Black; D E Thompson; W B Applegate; E Barrett-Connor; T A Musliner; L Palermo; R Prineas; S M Rubin; J C Scott; T Vogt; R Wallace; A J Yates; A Z LaCroix
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272

10.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

View more
  34 in total

1.  Therapy. Affect and affirmations--a 'basic' approach to promote adherence.

Authors:  William H Shrank; Niteesh K Choudhry
Journal:  Nat Rev Cardiol       Date:  2012-03-13       Impact factor: 32.419

Review 2.  Measuring and improving adherence to osteoporosis pharmacotherapy.

Authors:  Suzanne M Cadarette; Andrea M Burden
Journal:  Curr Opin Rheumatol       Date:  2010-07       Impact factor: 5.006

3.  Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule.

Authors:  D H Solomon; M A Brookhart; P Tsao; D Sundaresan; S E Andrade; K Mazor; R Yood
Journal:  Osteoporos Int       Date:  2010-09-29       Impact factor: 4.507

4.  Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial.

Authors:  S L Silverman; K Nasser; S Nattrass; B Drinkwater
Journal:  Osteoporos Int       Date:  2011-07-14       Impact factor: 4.507

5.  Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial.

Authors:  F A McAlister; C Ye; L A Beaupre; B H Rowe; J A Johnson; D Bellerose; I Hassan; S R Majumdar
Journal:  Osteoporos Int       Date:  2018-09-19       Impact factor: 4.507

6.  The economics of improving medication adherence in osteoporosis: validation and application of a simulation model.

Authors:  Amanda R Patrick; John T Schousboe; Elena Losina; Daniel H Solomon
Journal:  J Clin Endocrinol Metab       Date:  2011-07-06       Impact factor: 5.958

Review 7.  Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.

Authors:  M Hiligsmann; M Salas; D A Hughes; E Manias; F H Gwadry-Sridhar; P Linck; W Cowell
Journal:  Osteoporos Int       Date:  2013-05-01       Impact factor: 4.507

8.  Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication.

Authors:  A G G Stuurman-Bieze; E G Hiddink; J F M van Boven; S Vegter
Journal:  Osteoporos Int       Date:  2014-02-26       Impact factor: 4.507

9.  Limited Osteoporosis Screening Effectiveness Due to Low Treatment Rates in a National Sample of Older Men.

Authors:  Cathleen S Colón-Emeric; Carl F Pieper; Courtney H Van Houtven; Janet M Grubber; Kenneth W Lyles; Joanne Lafleur; Robert A Adler
Journal:  Mayo Clin Proc       Date:  2018-12       Impact factor: 7.616

10.  Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.

Authors:  Y Zhao; S S Johnston; D M Smith; D McMorrow; K Krohn; J Krege
Journal:  Osteoporos Int       Date:  2013-03-26       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.